BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29609040)

  • 1. Clinico-hematological profile and thrombotic/hemorrhagic events in 150 chinese patients with essential thrombocythemia.
    Zhou D; Chen W; Cheng H; Qiao JL; Zhu LL; Li ZY; Xu KL
    Leuk Res; 2018 Jun; 69():1-6. PubMed ID: 29609040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.
    Patriarca A; Pompetti F; Malizia R; Iuliani O; Di Marzio I; Spadano A; Dragani A
    Blood Transfus; 2010 Jan; 8(1):21-7. PubMed ID: 20104275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relationship between Thrombotic Events and Peripheral Neutrophil-to-lymphocyte Ratio in Patients with Newly Diagnosed Essential Thrombocythemia].
    Zhou D; Cheng H; Chen W; Li ZY; Xu KL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):534-538. PubMed ID: 30998166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
    Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
    Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia.
    Weston H; Cowell V; Grimmett K; Saal R; Jones M; Mills T; Gill D; Marlton P; Bird R; Mollee P
    Intern Med J; 2011 May; 41(5):408-15. PubMed ID: 20681956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between thrombotic risk scores in essential thrombocythemia and survival implications.
    Santoro M; Accurso V; Mancuso S; Carlisi M; Raso S; Tarantino G; Di Piazza F; Perez A; Russo A; Siragusa S
    Hematol Oncol; 2019 Oct; 37(4):434-437. PubMed ID: 31465530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extrinsic blood coagulation pathway and risk factors for thrombotic events in patients with essential thrombocythemia.
    Stankowska K; Gadomska G; Boinska J; Michalska M; Bartoszewska-Kubiak A; Rość D
    Pol Arch Med Wewn; 2016 May; 126(5):340-6. PubMed ID: 27243342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of JAK2V617F mutation on thrombosis and myeloid transformation in essential thrombocythemia: a multivariate analysis by Cox regression in 141 patients.
    Chim CS; Sim JP; Chan CC; Kho BC; Chan JC; Wong LG; Law M; Liang R; Kwong YL
    Hematology; 2010 Aug; 15(4):187-92. PubMed ID: 20670476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia.
    Latagliata R; Montanaro M; Cedrone M; Di Veroli A; Spirito F; Santoro C; Leonetti Crescenzi S; Porrini R; Di Giandomenico J; Villivà N; Spadea A; Rago A; De Gregoris C; Romano A; Anaclerico B; De Muro M; Felici S; Breccia M; Montefusco E; Bagnato A; Cimino G; Majolino I; Mazzucconi MG; Alimena G; Andriani A;
    Thromb Res; 2017 Aug; 156():168-171. PubMed ID: 28662484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: a multicenter study from Korea.
    Lee HS; Park LC; Lee EM; Lee SJ; Shin SH; Im H; Do KM; Kim EJ; Ye BJ; Song MK; Kim SH; Lee SM; Lee WS; Kim YS
    Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):70-5. PubMed ID: 22088920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia.
    Piccin A; Steurer M; Mitterer M; Blöchl EM; Marcheselli L; Pusceddu I; Marabese A; Bertozzi I; Corvetta D; Randi ML; Elli E; Pogliani EM; Veneri D; Perbellini O; Krampera M; Pacquola E; Gottardi M; Tiribelli M; Guella A; Innella B; Vivaldi P; De Biasi E; Sancetta R; Rocconi R; Bassan R; Gherlinzoni F; Pizzolo G; Gastl G; Cortelazzo S
    Intern Emerg Med; 2015 Jun; 10(4):451-60. PubMed ID: 25585678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
    Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between IPSET-t risk at diagnosis and subsequent hemorrhage in patients with essential thrombocythemia; a single institution experience.
    Tosoni L; Liberi M; Morelli G; Zannier ME; Lazzarotto D; Filì C; Simeone E; Battaglia G; Callegari C; Fanin M; Damiani D; Fanin R; Tiribelli M
    Ann Hematol; 2024 Feb; 103(2):443-448. PubMed ID: 38072850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients.
    Fu R; Xuan M; Lv C; Zhang L; Li H; Zhang X; Zhang D; Sun T; Xue F; Liu X; Liang H; Zhang L; Yang R
    Eur J Haematol; 2014 Jun; 92(6):502-9. PubMed ID: 24460750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Predictive Value of Neutrophil-Lymphocyte Ratio in Patients with Polycythemia Vera at the Time of Initial Diagnosis for Thrombotic Events.
    Wang X; Tu Y; Cao M; Jiang X; Yang Y; Zhang X; Lai H; Tu H; Li J
    Biomed Res Int; 2022; 2022():9343951. PubMed ID: 35978626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
    Alvarez-Larrán A; Pereira A; Guglielmelli P; Hernández-Boluda JC; Arellano-Rodrigo E; Ferrer-Marín F; Samah A; Griesshammer M; Kerguelen A; Andreasson B; Burgaleta C; Schwarz J; García-Gutiérrez V; Ayala R; Barba P; Gómez-Casares MT; Paoli C; Drexler B; Zweegman S; McMullin MF; Samuelsson J; Harrison C; Cervantes F; Vannucchi AM; Besses C
    Haematologica; 2016 Aug; 101(8):926-31. PubMed ID: 27175028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study.
    Palandri F; Polverelli N; Catani L; Ottaviani E; Baccarani M; Vianelli N
    Ann Hematol; 2011 Aug; 90(8):933-8. PubMed ID: 21287350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombosis and risk factors in female patients with a rare acquired thrombophilia: chronic myeloproliferative disorder - polycythaemia vera and essential thrombocythaemia.
    Pósfai É; Marton I; Kiss-László Z; Kotosz B; Széll M; Borbényi Z
    Eur Rev Med Pharmacol Sci; 2014; 18(24):3810-8. PubMed ID: 25555871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.